
Opinion|Videos|May 7, 2024
Clinical Efficacy of Non-Statin Treatment Options in ASCVD
Focusing on PCSK9 inhibitors, inclisiran, and bempedoic acid, the panel compares treatment efficacy and outlines patient factors that influence treatment decisions.
Advertisement
Episodes in this series

Advertisement
Related to this article

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Structured Blood Glucose Testing: Why Timing Matters
2
Glucose Monitoring: Timing Makes Every Reading Count
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
Navigating State Vaccine Regulations: Challenges for Community Pharmacies
5

